Biovitrum AB cuts staff as it restructures R&D ops
Sweden's Biovitrum AB has restructured its R&D operations, winnowing out about 100 people either through layoffs or by reassigning them to other work. Biovitrum says it will focus on specialist care pharmaceuticals and "is in the process of out-licensing a majority of the company's primary care projects."
- read the Biovitrum release for more info
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets